| Domain | Best-supported finding | Quantitative detail | Evidence type | Knowledge-base ontology suggestions |
|---|---|---|---|---|
| Disease identifiers | Revesz syndrome is an ultra-rare, severe pediatric telomere biology disorder within the dyskeratosis congenita spectrum, classically defined by bilateral exudative retinopathy plus intracranial calcification/cerebellar hypoplasia and early bone marrow failure; OMIM #268130 and MONDO:0009990 are supported in retrieved sources | 18 children summarized in the largest RS-specific review; all pediatric cases (pqac-00000004, pqac-00000003, pqac-00000013, pqac-00000000) | RS-specific systematic review + broader TBD review | MONDO:0009990; MeSH: Dyskeratosis Congenita; HPO: HP:0001872 Pancytopenia, HP:0000510 Blindness, HP:0009713 Nail dystrophy |
| Synonyms / nomenclature | RS is best treated as a disease-level, aggregated literature-defined syndrome; recent sources also describe it as an early severe pediatric TBD and a TINF2-associated dyskeratosis congenita variant | No EHR-derived cohort identified; evidence comes from published case reports/reviews (pqac-00000004, pqac-00000013) | RS-specific + broader TBD extrapolation | MONDO label plus exact synonym string: TINF2-associated dyskeratosis congenita with bilateral exudative retinopathy and intracranial calcification |
| Epidemiology / demographics | Extremely rare; no population prevalence or incidence was identified. Reported sex distribution does not support strong male predominance | 18 cases total; 7 female, 11 male; median survival 6.5 years; none survived beyond 12 years in the 2020 review (pqac-00000003, pqac-00000004) | RS-specific systematic review | HANCESTRO/NCIT demographic annotations as available; evidence gap flag for prevalence/incidence |
| Inheritance | RS is usually caused by de novo heterozygous TINF2 variants, although TINF2-related TBDs more broadly can also show autosomal dominant familial inheritance and anticipation | In reviewed RS cases, all genetically characterized patients reportedly had unaffected parents/de novo events; TINF2 often de novo in broader TBDs (pqac-00000003, pqac-00000027, pqac-00000016) | RS-specific + broader TBD extrapolation | HP:0000006 Autosomal dominant inheritance; HP:0032113 De novo mutation |
| Causal gene | TINF2 is the established causal gene for RS | Open Targets shows Revesz syndrome–TINF2 association; evidence size 5 (pqac-00000000) | Disease-target association + RS review | HGNC: TINF2; NCBI Gene: TINF2; GO CC: shelterin complex |
| Pathogenic variants | RS-associated variants cluster in TINF2 exon 6, especially around amino acids 280-289; p.Arg282His is the most recurrent hotspot. Truncating variants can also produce severe early phenotypes including RS | In historical TINF2-DC series, c.845G>A (p.Arg282His) accounted for 12 DC, 2 DC/RS, 1 DC/HH/RS probands; RS also reported with c.839delA (p.Lys280Argfs*36); mosaic c.865C>T (p.Pro289Ser) reported in an RS case (pqac-00000009, pqac-00000007, pqac-00000003) | RS-specific cases + TINF2 variant series | HGVS variant annotations; SO:0001583 missense_variant, SO:0001589 frameshift_variant, SO:0001587 stop_gained |
| Telomere biomarker | Very short telomeres are a defining functional biomarker in RS and early severe TBDs | In 7 RS patients with measurements, telomeres were below the 1st percentile for age; example RS case telomeres 2.47-2.48 kb (pqac-00000003, pqac-00000005, pqac-00000013) | RS-specific review/case + broader TBD review | HPO: HP:0034004 Short telomere; LOINC/assay annotation for flow-FISH telomere length |
| Core phenotype: bone marrow failure | Early bone marrow failure is universal or near-universal in RS and often the dominant life-limiting manifestation | All reviewed patients had early BMF; onset median 1.5 years, within second year; all by age 6 years (pqac-00000004, pqac-00000003) | RS-specific systematic review | HPO: HP:0001876 Pancytopenia, HP:0005528 Bone marrow hypocellularity |
| Core phenotype: retinopathy | Bilateral exudative retinopathy is a defining RS feature and can be the presenting manifestation | Retinopathy in all patients with available data; median onset 1.1 years, typically 6-18 months; severe visual loss common; glaucoma in 3 cases (pqac-00000004, pqac-00000003, pqac-00000007, pqac-00000013) | RS-specific systematic review + case reports | HPO: HP:0000555 Exudative retinopathy, HP:0011003 Retinal detachment, HP:0000501 Glaucoma; UBERON: retina |
| Core phenotype: intracranial abnormalities | Intracranial calcifications and cerebellar hypoplasia are common neurologic hallmarks; neurodevelopmental delay is frequent but variable | Intracranial calcifications 85%; cerebellar hypoplasia 76%; neurodevelopmental delay/mental retardation 71%; seizures about 20%; intracranial hemorrhage in 3 cases (pqac-00000003, pqac-00000002, pqac-00000013) | RS-specific systematic review + review | HPO: HP:0002521 Cerebral calcification, HP:0001321 Cerebellar hypoplasia, HP:0001263 Developmental delay, HP:0001250 Seizure |
| Other phenotype features | Classical dyskeratosis congenita mucocutaneous triad is less consistently expressed in RS, likely because of early severe course; growth restriction and fine/sparse hair are common | Only 2 RS cases had complete classic DKC triad in the 2020 review; growth retardation frequent qualitatively (pqac-00000001, pqac-00000013) | RS-specific review | HPO: HP:0001510 Growth delay, HP:0002219 Sparse hair, HP:0001597 Aplasia/hypoplasia of the skin pigmentation pattern |
| Mechanism | Germline TINF2 mutation disrupts TIN2, a central shelterin component linking TRF1/TRF2 with TPP1/POT1, leading to defective telomere protection/regulation, accelerated telomere shortening, stem-cell replicative exhaustion, and multisystem degeneration. Specific interaction defects vary by variant class | TIN2 mutants cluster in DC hotspot; truncation mutant severely impaired TRF1 interaction; TIN2L/TRF2 and TIN2L/TRF1 interactions are altered by DC-cluster mutations; TINF2 consequences considered multifactorial in broader TBD reviews (pqac-00000010, pqac-00000008, pqac-00000027, pqac-00000016) | Biochemical/in vitro + human genetics + broader TBD review | GO:0000784 nuclear chromosome telomeric region, GO:0032200 telomere organization, GO:0003691 double-stranded telomeric DNA binding, GO:0090398 cellular senescence |
| Cell and tissue vulnerability | High-turnover stem-cell compartments are most vulnerable; pathology extends beyond blood to retina/CNS and other organs. Tissue-specific shortening may be most severe outside donor-derived hematopoiesis | Broader TBD reviews emphasize HSCs, immune cells, intestinal cells, liver, lung, skin; autopsy in TINF2-DC showed shortest telomeres in lung, liver, kidney and age-appropriate donor hematopoietic tissue after transplant (pqac-00000016, pqac-00000030) | Broader TBD review + TINF2 human pathology case | CL: hematopoietic stem cell, lymphocyte; UBERON: bone marrow, retina, cerebellum, brain, liver, lung, kidney |
| Diagnostic workflow | Best-supported workup is clinical recognition of RS features plus telomere testing and germline sequencing of TINF2/TBD genes; flow-FISH is the current clinical standard for functional screening | Age-adjusted lymphocyte telomere length <1st percentile is the commonly used threshold; WES/WGS/panel sequencing recommended after short TL or strong suspicion; chromosome breakage testing is recommended to exclude Fanconi anemia (pqac-00000013, pqac-00000014, pqac-00000017, pqac-00000020) | Broader TBD review/guidance, applicable to RS | HPO terms above; LOINC assay for telomere length by flow-FISH; SO/ClinVar variant classification |
| Differential diagnosis | Main differentials are other TBDs and inherited bone marrow failure disorders, especially Hoyeraal-Hreidarsson syndrome, Coats plus syndrome, and Fanconi anemia | Coats plus may show exudative retinopathy but not necessarily short telomeres; Fanconi anemia exclusion by mitomycin C/DEB testing is recommended in transplant diagnostic pathways (pqac-00000013, pqac-00000014, pqac-00000022) | RS-specific/broader TBD reviews + trial eligibility criteria | MONDO/HPO mappings for Hoyeraal-Hreidarsson syndrome, Coats plus syndrome, Fanconi anemia |
| Prognosis | Prognosis is poor in RS, with death typically in childhood, although transplant may improve hematologic survival in some patients | Kaplan-Meier median survival 6.5 years (95% CI 3.6-9.4); no survival beyond 12 years in 2020 review (pqac-00000003, pqac-00000004) | RS-specific systematic review | NCIT prognosis annotation; HPO complication terms |
| Treatment: hematopoietic transplant | Allogeneic stem-cell transplantation is the only potentially curative therapy for marrow failure, but toxicity is a major concern; reduced-intensity, radiation/alkylator-sparing approaches are preferred in TBDs | In RS review, SCT in 8 children; 4 alive at last follow-up after median 22 months; deaths from pulmonary failure reported post-SCT. Broader TBD data note 10-year post-allo-SCT survival about 23% and benefit of non-myeloablative/radiation-avoiding protocols (pqac-00000004, pqac-00000002, pqac-00000018) | RS-specific review + broader TBD extrapolation | NCIT: Hematopoietic Stem Cell Transplantation; NCIT: Reduced-Intensity Conditioning Regimen |
| Treatment: ophthalmic interventions | Vision-preserving therapy is disease-modifying for the eye but evidence is case-based; laser photocoagulation appears most supported, with anti-VEGF and surgery used in selected eyes | Reported interventions include photocoagulation, intraocular bevacizumab, retinocryopexy, vitrectomy, enucleation; one mosaic TINF2 RS case retained VA 0.9 in treated eye at age 7 after photocoagulation (pqac-00000002, pqac-00000005, pqac-00000007) | RS-specific case reports/review | NCIT: Laser Photocoagulation; NCIT: Bevacizumab; NCIT: Vitrectomy; NCIT: Enucleation |
| Supportive management | Multidisciplinary surveillance is essential because complications extend across hematologic, ophthalmologic, pulmonary, hepatic, neurologic, mucocutaneous, and cancer domains | No RS-specific formal guideline retrieved; 2022-2024 TBD reviews/guidelines recommend surveillance, specialized-center care, and family counseling (pqac-00000026, pqac-00000018, pqac-00000019) | Broader TBD extrapolation | NCIT care pathway terms; HPO surveillance-linked phenotypes |
| Pharmacotherapy / experimental systemic therapy | No RS-specific drug proven effective. Broader TBD evidence supports androgen responsiveness in some patients and emerging nucleotide/telomerase-directed strategies | Broader TBD: danazol hematologic response 50-100% short-term; 11/12 gained telomere length with mean +386 bp after 24 months in one study summarized in review; applicability to RS is unproven (pqac-00000018, pqac-00000029, pqac-00000026) | Broader TBD extrapolation | CHEBI/DrugBank: danazol, oxymetholone, deoxycytidine, thymidine |
| Current RS-inclusive trials | RS is explicitly included in current TBD clinical trial frameworks rather than having RS-only trials | NCT01659606 active-not-recruiting phase 2 radiation- and alkylator-free HCT, estimated n=40, explicitly includes Revesz syndrome; NCT06817590 recruiting phase 1 oral deoxycytidine + deoxythymidine, estimated n=36, condition list explicitly includes Revesz syndrome; NCT04959188 completed needs-assessment study, n=53, included DC/TBD patients/caregivers (pqac-00000022, pqac-00000023, pqac-00000020, pqac-00000021, pqac-00000019) | Trial registry evidence | NCIT: Clinical Trial; NCIT: Alemtuzumab/Fludarabine conditioning; CHEBI: deoxycytidine, thymidine |
| Model organisms / cellular models | No RS-specific animal model was directly retrieved, but TINF2/TBD mechanistic modeling exists in mouse and pluripotent stem-cell systems | TIN2 biochemical cell models show altered shelterin interactions; iPSC DC models recapitulate telomere maintenance defects and loss of self-renewal; a cited mouse study found a DC-associated TINF2 mutation causes telomerase-independent telomere shortening (pqac-00000010, pqac-00000028, pqac-00000012) | In vitro/cellular + cited mouse-model evidence | MGI mouse model annotation; Cellosaurus/iPSC model tags; GO telomere maintenance |
| Environmental / modifier factors | No RS-specific environmental or protective factors were identified. In broader telomere disease literature, smoking, alcohol, viral infections, radiation, and pulmonary-toxic drugs may worsen organ phenotypes or treatment toxicity | Qualitative only; no RS-specific gene-environment study retrieved (pqac-00000029, pqac-00000014) | Broader TBD extrapolation | CHEBI exposure annotations; evidence-gap flag |
| Explicit evidence gaps | Major RS evidence gaps remain: prevalence/incidence, penetrance, founder effects, carrier frequency, modifier genes, protective factors, epigenetics, transcriptomics/proteomics/metabolomics, QoL metrics, standardized diagnostic criteria, and controlled treatment-response data | No robust RS-specific 2023-2024 cohort superseding the 2020 review was retrieved; most modern data are TBD-wide extrapolations (pqac-00000004, pqac-00000013, pqac-00000026) | Evidence-gap synthesis | Evidence code tags for "not available" / "broader TBD extrapolation only" |


*Table: This table condenses the strongest retrieved evidence for Revesz syndrome across identifiers, genetics, phenotype, mechanism, diagnosis, prognosis, treatment, trials, and evidence gaps. It distinguishes Revesz-specific findings from broader telomere biology disorder extrapolations for knowledge-base use.*